AU2007255110B8 - Circulating tumor cell assay - Google Patents

Circulating tumor cell assay Download PDF

Info

Publication number
AU2007255110B8
AU2007255110B8 AU2007255110A AU2007255110A AU2007255110B8 AU 2007255110 B8 AU2007255110 B8 AU 2007255110B8 AU 2007255110 A AU2007255110 A AU 2007255110A AU 2007255110 A AU2007255110 A AU 2007255110A AU 2007255110 B8 AU2007255110 B8 AU 2007255110B8
Authority
AU
Australia
Prior art keywords
igf
antibody
sample
patient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007255110A
Other languages
English (en)
Other versions
AU2007255110A1 (en
AU2007255110B2 (en
AU2007255110A8 (en
Inventor
David Allen Chianese
Mark Carle Connelly
Antonio Gualberto
Carrie Lynn Melvin
Madeline I. Repollet
Luisa Maria Roberts
Leonardus Wendelinus Mathias Marie Terstappen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Janssen Diagnostics LLC
Original Assignee
Pfizer Products Inc
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc, Veridex LLC filed Critical Pfizer Products Inc
Publication of AU2007255110A1 publication Critical patent/AU2007255110A1/en
Assigned to PFIZER PRODUCTS INC., VERIDEX, LLC reassignment PFIZER PRODUCTS INC. Amend patent request/document other than specification (104) Assignors: PFIZER PRODUCTS INC.
Application granted granted Critical
Publication of AU2007255110B2 publication Critical patent/AU2007255110B2/en
Publication of AU2007255110B8 publication Critical patent/AU2007255110B8/en
Publication of AU2007255110A8 publication Critical patent/AU2007255110A8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Sampling And Sample Adjustment (AREA)
AU2007255110A 2006-06-02 2007-05-29 Circulating tumor cell assay Ceased AU2007255110B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81081106P 2006-06-02 2006-06-02
US60/810,811 2006-06-02
PCT/IB2007/001483 WO2007141626A1 (en) 2006-06-02 2007-05-29 Circulating tumor cell assay

Publications (4)

Publication Number Publication Date
AU2007255110A1 AU2007255110A1 (en) 2007-12-13
AU2007255110B2 AU2007255110B2 (en) 2014-03-20
AU2007255110B8 true AU2007255110B8 (en) 2014-04-10
AU2007255110A8 AU2007255110A8 (en) 2014-04-10

Family

ID=38476880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007255110A Ceased AU2007255110B8 (en) 2006-06-02 2007-05-29 Circulating tumor cell assay

Country Status (19)

Country Link
US (4) US8940493B2 (cg-RX-API-DMAC7.html)
EP (1) EP2027470B1 (cg-RX-API-DMAC7.html)
JP (1) JP4943504B2 (cg-RX-API-DMAC7.html)
KR (3) KR20090023423A (cg-RX-API-DMAC7.html)
CN (1) CN101600966B (cg-RX-API-DMAC7.html)
AU (1) AU2007255110B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712225A8 (cg-RX-API-DMAC7.html)
CA (1) CA2653745C (cg-RX-API-DMAC7.html)
DK (1) DK2027470T3 (cg-RX-API-DMAC7.html)
ES (1) ES2397971T3 (cg-RX-API-DMAC7.html)
IL (1) IL195577A (cg-RX-API-DMAC7.html)
MX (1) MX2008015425A (cg-RX-API-DMAC7.html)
NZ (1) NZ573187A (cg-RX-API-DMAC7.html)
PL (1) PL2027470T3 (cg-RX-API-DMAC7.html)
PT (1) PT2027470E (cg-RX-API-DMAC7.html)
RU (1) RU2429486C2 (cg-RX-API-DMAC7.html)
SI (1) SI2027470T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007141626A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810203B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2007255110B8 (en) 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090258365A1 (en) * 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
JP6352588B2 (ja) 2009-10-21 2018-07-04 ザ スクリプス リサーチ インスティテュート 希少ではない細胞を用いて希少細胞を検出する方法
WO2011083391A2 (en) * 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
WO2012051390A1 (en) * 2010-10-14 2012-04-19 Veridex, Llc Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents
EP2668505A4 (en) * 2011-01-24 2014-05-21 Epic Sciences Inc METHOD FOR OBTAINING INDIVIDUAL CELLS AND APPLICATIONS FROM INDIVIDUAL YTOMICS
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
US9618515B2 (en) * 2011-07-21 2017-04-11 Janssen Diagnostics, Llc Assay to capture and detect circulating multiple myeloma cells from blood
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
WO2014028378A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Methods and systems for detecting biological components
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
EP3572788B1 (en) * 2012-10-26 2022-03-16 Fluidigm Canada Inc. Method for interrogating a biological sample
US9396532B2 (en) * 2012-11-15 2016-07-19 Siemens Healthcare Diagnostics, Inc. Cell feature-based automatic circulating tumor cell detection
CA3106271A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP3502270B1 (en) 2013-10-21 2020-03-18 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
CN103630440A (zh) * 2013-11-28 2014-03-12 武汉大学 一种循环肿瘤细胞的富集方法
WO2015112955A1 (en) 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
CN106061998B (zh) * 2014-02-05 2020-12-11 弗吉瑞必欧诊断股份公司 用于检测恶性赘生性疾病的组合物和方法
US10545151B2 (en) 2014-02-21 2020-01-28 Epic Sciences, Inc. Methods for analyzing rare circulating cells
CN103940997B (zh) * 2014-03-21 2017-01-04 上海柏慧康生物科技有限公司 一种乳腺癌循环肿瘤细胞检测系统及试剂盒
KR101656037B1 (ko) * 2014-04-30 2016-09-08 울산과학기술원 희소 세포 분리장치, 희소 세포 분리 방법 및 이를 이용한 희소 세포 검출 방법
EP3160654A4 (en) 2014-06-27 2017-11-15 The Regents of The University of California Pcr-activated sorting (pas)
WO2016033103A1 (en) * 2014-08-25 2016-03-03 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
CN104345052B (zh) * 2014-09-29 2017-10-20 南通市肿瘤医院 一种荧光负染法检测活细胞的方法
US10434507B2 (en) 2014-10-22 2019-10-08 The Regents Of The University Of California High definition microdroplet printer
CN107530654A (zh) 2015-02-04 2018-01-02 加利福尼亚大学董事会 通过在离散实体中条形码化对核酸进行测序
US20180066223A1 (en) 2015-04-17 2018-03-08 Xcell Biosciences, Inc. Cancer cell enrichment system
EP3286224A4 (en) * 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 dna 검출용 구조체 및 이의 용도
RU2616532C1 (ru) * 2015-12-28 2017-04-17 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ оценки чувствительности опухоли к проводимой химиотерапии больных местно-распространенным раком молочной железы
KR102130872B1 (ko) 2016-04-27 2020-07-06 주식회사 엘지화학 고체 시료의 수분 측정 장치, 고체 시료 수분 함량 측정 방법 및 이미드화율 분석 방법
US11142791B2 (en) 2016-08-10 2021-10-12 The Regents Of The University Of California Combined multiple-displacement amplification and PCR in an emulsion microdroplet
AU2017382905A1 (en) 2016-12-21 2019-07-04 The Regents Of The University Of California Single cell genomic sequencing using hydrogel based droplets
KR102888595B1 (ko) 2017-04-05 2025-11-20 필립모리스 프로덕츠 에스.에이. 유도 가열식 에어로졸 발생 장치 또는 시스템과 함께 사용하기 위한 서셉터
US10501739B2 (en) 2017-10-18 2019-12-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
EP3540631A1 (de) 2018-03-15 2019-09-18 Siemens Healthcare GmbH In-vitro-verfahren zum markierungsfreien bestimmen eines zelltyps einer weissen blutzelle
CN109406245A (zh) * 2018-09-12 2019-03-01 中国辐射防护研究院 一种电子线照射对小鼠igf相关蛋白表达影响的检测方法
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
WO2021003255A1 (en) 2019-07-01 2021-01-07 Mission Bio Method and apparatus to normalize quantitative readouts in single-cell experiments
KR20240157060A (ko) 2022-03-30 2024-10-31 니뽄 다바코 산교 가부시키가이샤 비연소 가열형 향미 흡인 물품에 이용하는 향미 시트
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018757A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Stabilization of cells and biological specimens for analysis
WO2003065042A1 (en) * 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551435A (en) * 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4925788A (en) * 1986-10-24 1990-05-15 Immunicon Corporation Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
US5108933A (en) * 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
US5200084A (en) * 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
JP2000508171A (ja) * 1996-04-05 2000-07-04 ザ・ジョンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 希少細胞の富化方法
US20010018192A1 (en) * 1998-02-12 2001-08-30 Terstappen Leon W.M.M. Labeled cells for use as an internal functional control in rare cell detection assays
WO1999041613A1 (en) * 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
CA2350692A1 (en) 1998-10-29 2000-05-11 Cell Works Diagnostics, Inc. Multiple marker characterization of single cells
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
JP2001041959A (ja) * 1999-05-24 2001-02-16 Toray Ind Inc 癌細胞検出システムおよび癌細胞検出キット
CA2380953A1 (en) 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
NZ537458A (en) * 2001-01-23 2007-02-23 Primagen Holding B Means and methods for treatment evaluation
US7863012B2 (en) * 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
US6670142B2 (en) * 2001-10-26 2003-12-30 The Regents Of The University Of California Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells
ES2283759T3 (es) * 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2006041453A1 (en) 2004-09-30 2006-04-20 Immunivest Corporation Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients
DK1861509T3 (da) 2005-03-14 2015-12-07 Janssen Diagnostics Llc Fremgangsmåde til forudsigelse af progressionsfri og overordnet overlevelse for hvert opfølgningstidspunkt under behandling af patienter med metastatisk brystkræft under anvendelse af cirkulerende tumorceller
US20070037173A1 (en) * 2005-08-12 2007-02-15 Allard Jeffrey W Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients
AU2007255110B8 (en) 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
US9121801B2 (en) * 2007-10-24 2015-09-01 Biomarker Strategies, Llc Methods and devices for cellular analysis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065042A1 (en) * 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2003018757A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Stabilization of cells and biological specimens for analysis
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAYES, DF et al. International Journal of Oncology, November 2002, Vol.21, No.5, pages 1111-1117. *
KAGAN, M. et al. Journal of Clinincal Ligand Assay, March 2002, Vol.25, No.1, pages 104-110. *
LARSON, CJ et al. Cytometry A, November 2004, Vol.62, No.1, pages 46-53. *
MORENO, JG et al. Urology, April 2005, Vol.65, No.4, pages 713-718 *
RAO, C. et al. Proceedings of the Annual Meeting of the American Association for Cancer Research, March 2004, Vol.45, page 763 *

Also Published As

Publication number Publication date
CN101600966A (zh) 2009-12-09
US20200191793A1 (en) 2020-06-18
KR101467136B1 (ko) 2014-12-01
EP2027470B1 (en) 2012-11-21
IL195577A (en) 2012-12-31
RU2008147415A (ru) 2010-06-10
CN101600966B (zh) 2014-07-02
WO2007141626A8 (en) 2009-01-08
AU2007255110A1 (en) 2007-12-13
KR20140052081A (ko) 2014-05-02
US20100028915A1 (en) 2010-02-04
US8940493B2 (en) 2015-01-27
ES2397971T3 (es) 2013-03-12
SI2027470T1 (sl) 2013-01-31
MX2008015425A (es) 2008-12-12
US20180011103A1 (en) 2018-01-11
JP2009539097A (ja) 2009-11-12
IL195577A0 (en) 2009-09-01
AU2007255110B2 (en) 2014-03-20
PL2027470T3 (pl) 2013-03-29
CA2653745C (en) 2013-11-19
RU2429486C2 (ru) 2011-09-20
DK2027470T3 (da) 2013-02-04
BRPI0712225A2 (pt) 2012-07-24
WO2007141626A1 (en) 2007-12-13
CA2653745A1 (en) 2007-12-13
PT2027470E (pt) 2013-01-28
BRPI0712225A8 (pt) 2019-01-22
US20150177252A1 (en) 2015-06-25
ZA200810203B (en) 2020-05-27
NZ573187A (en) 2011-11-25
KR20090023423A (ko) 2009-03-04
EP2027470A1 (en) 2009-02-25
AU2007255110A8 (en) 2014-04-10
JP4943504B2 (ja) 2012-05-30
KR20130091788A (ko) 2013-08-19
HK1137509A1 (en) 2010-07-30

Similar Documents

Publication Publication Date Title
AU2007255110B2 (en) Circulating tumor cell assay
Ludovini et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
Lüftner et al. Serum HER-2/neu in the management of breast cancer patients
Smerage et al. Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer
Cabioglu et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow
Tu et al. CellSearch® technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis
CA2623445A1 (en) Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
US7794960B2 (en) Predictive biomarkers in cancer therapy
Mascaux et al. EGFR protein expression in non–small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor—A novel antibody for immunohistochemistry or AQUA technology
Ryu et al. Impact of serum HER2 levels on survival and its correlation with clinicopathological parameters in women with breast cancer
Milman et al. Medullary thyroid cancer that stains negative for CA 19-9 has decreased metastatic potential
Witzel et al. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer
Nanguzgambo et al. Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy
HK1137509B (en) Circulating tumor cell assay
Kong et al. Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer
Słodkowska et al. Digital pathology in personalized cancer therapy
Kim et al. Establishment for reference range of serum HER-2/neu in Korean healthy women
Mahmoud Early detection of malignant pleural mesothelioma
Herrspiegel et al. serUM-Px Liquid Biopsies Predicts Mortality in Uveal Melanoma
JP2023177246A (ja) 乳がん患者の予後を予測する方法
Ma et al. Study on serum HER2 extracellular domain expression in early stage breast cancer patients
Müller Sentinel Lymph
van Halteren et al. Early Breast Cancer Agressiveness does not Differ Between Insulin-Sensitive and Insulin-Resistant Postmenopausal Non-Diabetic Women

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 23 , NO 1 , PAGE(S) 6092 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PFIZER PRODUCTS INC.; VERIDEX, LLC, APPLICATION NO. 2007255110, UNDER INID (72) CORRECT THE CO-INVENTOR TO CONNELLY, MARK CARLE

Free format text: IN VOL 28 , NO 11 , PAGE(S) 1551 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME PFIZER PRODUCTS INC.; VERIDEX, LLC, APPLICATION NO. 2007255110, UNDER INID (72) CORRECT THE CO-INVENTOR TO CONNELLY, MARK CARLE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired